Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 002 and POLB 003. The Company is focused on developing two oral delivery platforms targeting areas of unmet medical need that include oral vaccine delivery, which is delivering immune-stimulating antigens to specific areas of the gut using encapsulation technologies, and oral delivery of metabolic disease treatments, which is a delivery system that offers generally regarded as safe (GRAS) approved solution for the oral delivery of GLP-1/metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes and other metabolic diseases. It uses artificial intelligence to identify infectious disease drug targets and treatments.